(Q38036618)

27 August 2017

title

Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: I. aztreonam and carbapenems (English)

1 reference

27 August 2017

main subject

carbapenem antibiotic

0 references

0 references

0 references

1 reference

Jeffery T Zobell

1

1 reference

27 August 2017

David C Young

2

1 reference

27 August 2017

C Dustin Waters

3

1 reference

27 August 2017

Chris Stockmann

4

1 reference

27 August 2017

Krow Ampofo

5

1 reference

27 August 2017

Catherine M T Sherwin

6

1 reference

27 August 2017

Michael G Spigarelli

7

1 reference

27 August 2017

publication date

21 August 2012

1 reference

27 August 2017

published in

Pediatric Pulmonology

1 reference

27 August 2017

volume

47

1 reference

27 August 2017

issue

12

1 reference

27 August 2017

page(s)

1147-1158

1 reference

Management of pulmonary disease in patients with cystic fibrosis

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22655

Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22655

Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22655

Nonpharmacologic airway clearance therapies: ACCP evidence-based clinical practice guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22655

Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22655

A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22655

Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22655

Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22655

Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22655

Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22655

A survey of the utilization of anti-pseudomonal beta-lactam therapy in cystic fibrosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22655

A survey of once-daily dosage tobramycin therapy in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22655

Use of pharmacokinetics and pharmacodynamics to optimize antimicrobial treatment of Pseudomonas aeruginosa infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22655

Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22655

Pharmacokinetics and pharmacodynamics of cefepime administered by intermittent and continuous infusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22655

Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22655

Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22655

High dose intermittent ticarcillin-clavulanate administration in pediatric cystic fibrosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22655

A comparison of aztreonam and ceftazidime in the treatment of respiratory infections in adults with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22655

Continuous versus intermittent infusions of ceftazidime for treating exacerbation of cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22655

The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22655

Pharmacokinetics of aztreonam in healthy subjects and patients with cystic fibrosis and evaluation of dose-exposure relationships using monte carlo simulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22655

Pharmacokinetics, safety, and tolerability of doripenem after 0.5-, 1-, and 4-hour infusions in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22655

Pharmacokinetics of imipenem and cilastatin in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22655

Combined imipenem/cilastatin and tobramycin therapy of multiresistant Pseudomonas aeruginosa in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22655

Pharmacokinetics of high-dose meropenem in adult cystic fibrosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22655

In vitro activity of doripenem (S-4661) against multidrug-resistant gram-negative bacilli isolated from patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22655

In vitro activity of doripenem against Pseudomonas aeruginosa and Burkholderia cepacia isolates from both cystic fibrosis and non-cystic fibrosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22655

Clinical evaluation of meropenem versus ceftazidime for the treatment of Pseudomonas spp. infections in cystic fibrosis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22655

Carbapenem stewardship: positive impact on hospital ecology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22655

Carbapenem stewardship: does ertapenem affect Pseudomonas susceptibility to other carbapenems? A review of the evidence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22655

Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22655

Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22655

Antimicrobial Resistance: Pharmacokinetics‐Pharmacodynamics of Antimicrobial Therapy: It’s Not Just for Mice Anymore

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22655

21 January 2018

Identifiers

DOI

10.1002/PPUL.22655

1 reference

27 August 2017

1 reference